(Q36832141)

16 August 2017

1 reference

title

Novel antibodies as anticancer agents (English)

1 reference

16 August 2017

1 reference

Zafir-Lavie I

1

1 reference

16 August 2017

Michaeli Y

series ordinal

2

1 reference

16 August 2017

Reiter Y

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

25

1 reference

16 August 2017

page(s)

3714-3733

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210372

16 August 2017

exact match

0 references

cites work

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Lymphangiogenesis in development and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Chemokines and leukocyte traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A cytotoxic DNA precursor is taken up selectively by human cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A cytotoxic agent can be generated selectively at cancer sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Ribosome-inactivating proteins from plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Generation of a novel anti-geldanamycin antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Role of tumor-associated gangliosides in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Tumor escape from immune response by variation in HLA expression and other mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Ribosome-inactivating and adenine polynucleotide glycosylase activities in Mirabilis jalapa L. tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Genetic instability and darwinian selection in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antiangiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Recombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Active and inactive conformations of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Rescue of a neutralizing anti-viral antibody fragment from an intracellular polyclonal repertoire expressed in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Epidermal growth factor receptor inhibition strategies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antibody phage display technology and its applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Tumor-induced immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Intrabodies: turning the humoral immune system outside in for intracellular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Ribosome-inactivating proteins from plants: more than RNA N-glycosidases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The biology of chemokines and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Antibody phage display technologies with special reference to angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Intrabodies as drug discovery tools and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Searching for MHC-restricted anti-viral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Are tumours angiogenesis-dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The IL-2/IL-15 receptor systems: targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The multichain interleukin-2 receptor: a target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Signaling defects in T lymphocytes of patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

TRAIL and its receptors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies i

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

High level secretion of a humanized bispecific diabody from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Correctly Folded T-cell Receptor Fragments in the Periplasm of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for Therapy of Cutaneous T Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

A monoclonal antibody recognizes a subset of the H-2Dd mouse major class I antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Polynucleotide: adenosine glycosidase activity of immunotoxins containing ribosome-inactivating proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Targeted tumor killing via an intracellular antibody against erbB-2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Mechanism of action of ricin and related toxins on the inactivation of eukaryotic ribosomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Cancer-associated glycosphingolipid antigens: their structure, organization, and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Properties of bispecific single chain antibodies expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Cytokines and immune response in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Recombinant toxins as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Cytokine gene therapy or infusion as treatment for solid human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Generation of DOTA-conjugated antibody fragments for radioimmunoimaging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210372

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210372

1 reference

Dimensions Publication ID

16 August 2017

1004962367

0 references

1 reference